The FDA has issued warning letters to stem cell and HCT/P providers for years, and the violations cited fall into a recognizable pattern, almost all of them rooted in 21 CFR Part 1271. Reading that pattern is more useful to a physician than memorizing any single letter, because it shows precisely what the agency looks for. The letters are public record, searchable by anyone, including patients, attorneys, payers, and state medical boards. What follows is the recurring violation set drawn from the FDA’s public warning-letter record and a self-audit a physician can run against it.
TLDR: FDA warning letters in the HCT/P space cluster around a consistent set of violations: manufacturing without establishment registration (21 CFR 1271.21), using more-than-minimally-manipulated products without an IND (21 CFR 312.2), non-homologous use without an IND (21 CFR 1271.10), CGTP non-compliance (Subpart D of 1271), donor-eligibility failures (21 CFR 1271.50), and labeling deficiencies (1271.250 to 1271.290). The agency expects a written response within 15 business days, and unresolved letters can lead to injunction, seizure, or criminal referral. Letters are permanent public record. Banking adipose tissue does not enroll a patient in therapy and does not guarantee any future eligibility, access, or benefit.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. No adipose-derived stem cell product currently holds FDA approval for the conditions discussed in this article. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
A warning letter is not the end of a process; it is the documented middle of one. By the time the FDA sends it, the agency has identified a specific violation and is on record about it, which is why the letter’s real value to other physicians is diagnostic. The same handful of failures appears again and again, and a practice that audits itself against them is auditing against the FDA’s actual enforcement priorities rather than a guess at them.
What an FDA Warning Letter Is and Why It Matters
A warning letter is an official FDA communication that identifies a specific violation of law or regulation and requests corrective action. It is posted to the FDA’s public warning letters database and is searchable by anyone. It is not a final enforcement action, but it signals that the agency has documented a violation and is watching, and an inadequate response can escalate to injunction, product seizure, or criminal referral. In the stem cell space, the FDA has issued these letters since at least 2017, with a notable acceleration through 2019 to 2022, and the activity has continued since. The letters do not expire or get removed, which is why a single one can follow a practice indefinitely.
The Most Commonly Cited Violations
Drawn from the FDA’s public HCT/P warning letters, the recurring categories are consistent. Manufacturing HCT/Ps without proper establishment registration under 21 CFR 1271.21, operating without registering through the establishment registration system. Manufacturing more-than-minimally-manipulated HCT/Ps without an IND under 21 CFR 312.2, administering products the FDA considers to require an IND because they fail the 361 criteria. Non-homologous use without an IND under 21 CFR 1271.10, using tissue for purposes outside its basic function. CGTP non-compliance under Subpart D of Part 1271, covering inadequate procedures, environmental monitoring, personnel training, or recordkeeping. Donor-eligibility failures under 21 CFR 1271.50, where allogeneic tissue is used without the required screening and testing. And labeling deficiencies under 21 CFR 1271.250 through 1271.290, where required label elements are missing or incomplete. Inadequate infection-control procedures appear alongside these as a recurring safety theme.
The Real-World Record
Rather than reconstruct the specifics of individual letters from memory, which risks error, the reliable approach is to consult the FDA’s public database directly. The agency’s warning letters database is searchable by term, and a search for stem cell or HCT/P returns the actual correspondence, including the named recipient, the cited violations, and the agency’s required corrective actions. The widely reported FDA actions against operators of adipose-derived cell products are findable there, as are letters concerning birth-tissue and umbilical-cord products marketed for unapproved uses. A physician evaluating a supplier or auditing their own practice should pull the primary letters from that database rather than rely on any summary, because the specific cited regulation and the agency’s reasoning are what matter, and those are only reliable from the source document.
The Pattern: What the FDA Is Looking For
Synthesized, the warning-letter record points at a small number of behaviors. Manufacturing or using an isolated cellular fraction of adipose tissue without an IND, which fails on two independent grounds, since extracting such cells is more than minimal manipulation and systemic infusion is non-homologous, a distinction set out in the explainer on intact adipose tissue. Operating facilities without FDA registration. Using adipose-derived cells for conditions far outside any homologous function, such as neurological disease, autism, or pulmonary disease, a hallmark of the operators flagged in the guide on spotting fake stem cell clinics. Making marketing claims inconsistent with the product’s regulatory classification, including implying FDA approval where none exists. And failing to keep records that would let the FDA trace products through the supply chain. Every item on that list is preventable, and most map directly to a verification step a practice can build into intake.
Warning Letter Violation Categories
| Violation | CFR cite | How it is triggered | How to avoid it |
|---|---|---|---|
| No establishment registration | 21 CFR 1271.21 | Operating without registering through the establishment system | Register before operations; renew annually each December |
| More than minimal manipulation without IND | 21 CFR 312.2 | Using isolated fraction or enzymatically processed cells | Verify regulatory classification with counsel before use |
| Non-homologous use without IND | 21 CFR 1271.10 | Injecting adipose cells for systemic or non-structural conditions | Confirm homologous use for each intended clinical use |
| CGTP non-compliance | 21 CFR 1271.150-440 | Inadequate procedures, no environmental monitoring, no training | Audit the lab partner against a CGTP checklist |
| Donor-eligibility failure | 21 CFR 1271.50 | Using allogeneic tissue without screening and testing | Use autologous tissue, or verify allogeneic eligibility documentation |
| Labeling deficiencies | 21 CFR 1271.250-290 | Missing required label information | Review all labeling against Part 1271 before use |
What Happens After a Warning Letter
The FDA generally expects a written response within 15 business days that addresses each cited violation and describes the corrective actions taken. If the response is inadequate or absent, the agency may pursue an injunction to halt operations, seize products, or refer the matter to the Department of Justice for criminal action. A state medical board may also act independently once a physician’s practice receives a federal warning letter, so the consequences are not confined to the FDA. And because the letters are permanent public record, the reputational and discovery exposure persists long after any underlying issue is resolved.
Self-Audit Checklist
- Establishment registration confirmed and current.
- Every HCT/P used has a written 361 classification determination from the processing facility.
- Intended use for each product confirmed as homologous.
- Lab partner CGTP compliance verified.
- Donor-eligibility procedures in place for any allogeneic tissue.
- All labeling reviewed against 21 CFR 1271.250 to 1271.290.
- No marketing claims implying FDA approval for unapproved therapies.
- No disease cure or treatment claims in any marketing material.
- Legal counsel has reviewed the practice’s overall HCT/P compliance program.
Frequently Asked Questions
Is a warning letter the same as an enforcement action?
No. A warning letter identifies a documented violation and requests correction. It is not itself a final action, but failure to respond adequately can escalate to injunction, seizure, or criminal referral.
Where can I read the actual stem cell warning letters?
In the FDA’s public warning letters database, searchable by term such as stem cell or HCT/P. The source letters give the named recipient, the specific regulation cited, and the corrective actions required, which a summary cannot reliably reproduce.
How quickly must a recipient respond?
The FDA generally expects a written response within 15 business days addressing each violation and the corrective actions taken.
Key Takeaways
The warning-letter record in regenerative medicine is repetitive, which is what makes it useful: the same violations recur, so a practice can audit against them directly. Registration failures, more-than-minimal-manipulation and non-homologous use without an IND, CGTP gaps, donor-eligibility lapses, and labeling deficiencies are the core set, and an isolated cellular fraction used systemically tends to fail on multiple grounds at once. The letters are public and permanent, the response window is short, and the consequences of an inadequate response escalate quickly and can pull in a state board. The honest way to study the specifics is to read the primary letters in the FDA’s database rather than any secondhand account. None of this concerns banking, which is a preservation decision separate from any therapeutic use and carries no guarantee of future benefit, but the verification habits that prevent a warning letter are the same habits a careful banking practice already runs.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Physicians building a warning-letter-prevention audit can contact Save My Fat to discuss how tissue preservation and sourcing fit. Service and processing details are available at https://savemyfat.com/pricing/.
Save My Fat partners with L2 Bio for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about neurologic treatment or research participation.
